SCI论文写作格式及投稿注意事项
科研论文是对科学领域中的问题进行总结、研究、探讨，表述科学研究成果的论文，下面是小编搜集整理的SCI论文格式及投稿注意事项，欢迎阅读查看。
一：论文的文题
作用
反映论文的主题或主要信息
吸引读者
要求
一般不超过100个字母
排版后不超过2行
可以不是完整的句子
最好反映文章的特色，如：若是随机对照试验，文题需要体现
最好反映研究对象，如动物种类等
二：关键词
一般列出3~10个,应尽量按照美国国立医学图书馆编纂的《Index Medicus》中的MeSH表选词。
如果MeSH表中找不到，可以用新词或相近的词
三：论文摘要
200-300字
一般为四要素结构式，包括Objective (Background), Methods, Results, Conclusion
JAMA分Context, Objective, Design and setting, Patients, Interventions， Main outcome measures, Results, Conclusions
目的(背景)
Background Eltrombopag is a new, orally active thrombopoietin-receptor agonist that stimulates thrombopoiesis. We evaluated its ability to increase platelet counts and facilitate treatment for hepatitis C virus (HCV) infection in patients with thrombocytopenia associated with HCV-related cirrhosis.
方法
Methods Seventy-four patients with HCV-related cirrhosis and platelet counts of 20,000 to less than 70,000 per cubic millimeter were randomly assigned to receive eltrombopag (30, 50, or 75 mg daily) or placebo daily for 4 weeks. The primary end point was a platelet count of 100,000 per cubic millimeter or more at week 4. Peginterferon and ribavirin could then be initiated, with continuation of eltrombopag or placebo for 12 additional weeks.
结果
Results At week 4, platelet counts were increased to 100,000 per cubic millimeter or more in a dose-dependent manner among patients for whom these data were available: in 0 of the 17 patients receiving placebo, in 9 of 12 (75%) receiving 30 mg of eltrombopag, in 15 of 19 (79%) receiving 50 mg of eltrombopag, and in 20 of 21 (95%) receiving 75 mg of eltrombopag (P<0.001). Antiviral therapy was initiated in 49 patients (in 4 of 18 patients receiving placebo, 10 of 14 receiving 30 mg of eltrombopag, 14 of 19 receiving 50 mg of eltrombopag, and 21 of 23 receiving 75 mg of eltrombopag) while the administration of eltrombopag or placebo was continued. Twelve weeks of antiviral therapy, with concurrent receipt of eltrombopag or placebo, were completed by 36%, 53%, and 65% of patients receiving 30 mg, 50 mg, and 75 mg of eltrombopag, respectively, and by 6% of patients in the placebo group. The most common adverse event during the initial 4 weeks was headache; thereafter, the adverse events were those expected with interferon-based therapy.
结论
Conclusions Eltrombopag therapy increases platelet counts in patients with thrombocytopenia due to HCV-related cirrhosis, thereby permitting the initiation of antiviral therapy.
四：论文引言
需要交待研究的背景
需要交待本文要做什么
需要引用相关参考文献
300字左右
In this phase 2 study, we assessed whether the use of eltrombopag can increase platelet counts in patients with thrombocytopenia associated with cirrhosis due to chronic HCV infection. The safety and adverse-event profiles of eltrombopag were also evaluated.
五：材料和方法
应明确说明选择的观察或实验对象(患者或实验动物，包括对照)
描述受试者的年龄、性别和其他重要特征，明确研究对象是如何选择的`。
应说明研究的地点，以及诊断、纳入和剔除标准。
详细介绍研究方法、仪器和操作程序。
使用已有的方法，应标明参考文献;对已经发表但大家不是很熟悉的方法，不仅要给出参考文献，还要做简要说明;如使用的是新的或经过修改的方法，应说明使用的原因，并评价其局限性。
对使用的药物或化学制品，应介绍其通用名称、剂量和使用途径。
第一次描述产品时，要交代生产厂家和国家名称
应简要介绍所采用的统计学分析方法、采用的软件及版本，并注明检验水准。
材料与方法交代的是否清楚，要看读者看后能重复试验。
Primary and Secondary End Points
The primary end point was the proportion of patients who had door-to-balloon times within the 90-minute recommended guideline. …
Secondary end points included mortality, reinfarction, stroke, cardiogenic shock, and major bleeding. …
Statistical Analysis
Categorical variables were compared with the use of Fisher's exact test. Normally distributed continuous variables were compared with Student's t-test. Time intervals were analyzed with the Mann–Whitney U test. Analyses were conducted with the use of Systat software, version 11.0 (Systat). A P value of 0.05 or less was considered to indicate statistical significance.
六：论文结果
应围绕研究的主题，用文字、图表有逻辑地、有层次地列出。
先主要结果，后次要结果
能用图表的尽量用图表。
图表所示与文字表述尽量不要重复。
对于与研究假设或与研究者的主观愿望相违的结果，也应如实报告，不能随意取舍。
要根据结果下结论，而不是根据结论安排结果。
作者有义务报告阴性结果
要重视对失访者的追踪和描述(intention-to-treat analysis)
Results
Characteristics of the Patients
Between May 1, 2005, and April 30, 2006, a total of 344 patients with confirmed ST-segment elevation myocardial infarction were referred for primary PCI to the cardiac care center.
七：论文的讨论
第一段要指出本研究的重要结果和新发现
要把本结果和国内外其他相关结果进行分析，指出和其它研究的异同及原因
要指出本研究的不足
最后做小结和展望
Discussion
We identified regions of rare copy-number variation in families with autism and observed an association between a microdeletion on chromosome 16 (and the inherited reciprocal duplication) and autism. …
Several limitations of our trial should be mentioned. The vasopressin was infused over a set range of doses, and we did not measure vasopressin levels as a guide to the dose or the duration of infusion. …
In conclusion, our data indicate that a region of chromosome 16p11.2 influences susceptibility to autism when it is either deleted or duplicated. …
【SCI论文写作格式及投稿注意事项】相关文章：